To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Postherpetic Neuralgia.

Phase 3

Completed

• Conditions: Neuralgia

• Registration Number: NCT00150436
• Lead Sponsor: Pfizer

Brief Summary

To evaluate long-term safety and efficacy of pregabalin in patients with postherpetic neuralgia.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-02
• Study Completion: 2005-07
• Study First Submitted: 2005-09-06
• Study First Submitted QC: 2005-09-06
• Study First Posted: 2005-09-08
• Status Verified: 2006-12
• Last Update Submitted: 2006-12-20
• Last Update Posted: 2006-12-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 276

Inclusion Criteria

• Must have met the inclusion criteria for preceding double-blind BID study in postherpetic neuralgia
• Must have received pregabalin/placebo under double-blind conditions for a minimum of 3 weeks.

Exclusion Criteria

• Patients cannot participate if they experienced a serious adverse event during preceding double-blind BID study which was determined to be related to the study medication.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Safety Efficacy